SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Howard Henick who wrote (218)8/17/1997 1:39:00 PM
From: NeuroInvestment   of 675
 
1) August 1 I placed CNSI back on 'speculative buy' status since it was down so near cash value. While stroke has a best case scenario of an 18-24 month delay, head trauma remains a very viable (but still speculative) indication. CNS1561 will reach Ph I in the next month or two, but this means nothing is within 18-24 months of a Ph III besides Cerestat. The downside risk is cushioned by cash.
2) I actually recommended CoCensys June 1 when it was overly punished after Novartis bailed out on ACEA 1021. They have a workaround strategy for the renal issue that seems doable. By year end Ph II data should be in for migraine and epilepsy, Ph I for insomnia. Cash remains low but they have four programs that are all attractive to Big Pharma collaborator candidates. Thus I expect good recovery by year-end. Hope this answers your questions. NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News